Agid O, Kapur S, Arenovich T, Zipursky RB (2003). Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 60: 1228–1235.
Arnold JC, Hone P, Holland ML, Allen JD (2012). CB2 and TRPV1 receptors mediate cannabinoid actions on MDR1 expression in multidrug resistant cells. Pharmacol Rep 64: 751–757.
Bendayan R, Ronaldson PT, Gingras D, Bendayan M (2006). In situ localization of P-glycoprotein (ABCB1) in human and rat brain. J Histochem Cytochem 54: 1159–1167.
Boucher AA, Hunt GE, Karl T, Micheau J, McGregor IS, Arnold JC (2007). Heterozygous neuregulin 1 mice display greater baseline and Delta(9)-tetrahydrocannabinol-induced c-Fos expression. Neuroscience 149: 861–870.
Boucher AA, Hunt GE, Micheau J, Huang X, McGregor IS, Karl T et al (2011). The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. Int J Neuropsychopharmacol 14: 631–643.
Boulton DW, DeVane CL, Liston HL, Markowitz JS (2002). In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 71: 163–169.
Brzozowska N, Li KM, Wang XS, Booth J, Stuart J, McGregor IS et al (2016). ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice. PeerJ 4: e2081.
Csomor PA, Preller KH, Geyer MA, Studerus E, Huber T, Vollenweider FX (2014). Influence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy 'low and high gating' humans and relation to psychometry. Neuropsychopharmacology 39: 2485–2496.
De Klerk OL, Bosker FJ, Luurtsema G, Nolte IM, Dierckx R, Den Boer JA et al (2011). The role of p-glycoprotein in psychiatric disorders: a reliable guard of the brain? Cent Nerv Syst Agents Med Chem 11: 197–209.
De Klerk OL, Willemsen AT, Bosker FJ, Bartels AL, Hendrikse NH, den Boer JA et al (2010). Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: a PET study with [11C] verapamil as a probe for P-glycoprotein function. Psychiatry Res 183: 151–156.
Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E et al (2005). The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 33: 165–174.
Downer EJ, Clifford E, Amu S, Fallon PG, Moynagh PN (2012). The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-beta expression via peroxisome proliferator-activated receptor-alpha. J Biol Chem 287: 25440–25453.
Fakhfouri G, Ahmadiani A, Rahimian R, Grolla AA, Moradi F, Haeri A (2012). WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-gamma pathway. Neuropharmacology 63: 653–666.
Fibiger H (1994). Neuroanatomical targets of neuroleptic drugs as revealed by Fos immunochemistry. J Clin Psychiatry 55(Suppl B): 33–36.
Food and Drug Administration (2005) Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers. Food and Drug Administration: Rockville, MD, USA.
Fujimura M, Hashimoto K, Yamagami K (2000). The effect of the antipsychotic drug mosapramine on the expression of Fos protein in the rat brain: comparison with haloperidol, clozapine and risperidone. Life Sci 67: 2865–2872.
Gazzin S, Strazielle N, Schmitt C, Fevre-Montange M, Ostrow JD, Tiribelli C et al (2008). Differential expression of the multidrug resistance-related proteins ABCb1 and ABCc1 between blood-brain interfaces. J Comp Neurol 510: 497–507.
Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001). Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade inreview. Psychopharmacology 156: 117–154.
Glennon RA, Titeler M, McKenney J (1984). Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 35: 2505–2511.
Golech SA, McCarron RM, Chen Y, Bembry J, Lenz F, Mechoulam R et al (2004). Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res Mol Brain Res 132: 87–92.
Green AI, Burgess ES, Dawson R, Zimmet SV, Strous RD (2003). Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res 60: 81–85.
Gunasekaran N, Long L, Dawson B, Hansen G, Richardson D, Li K et al (2009). Reintoxication: the release of fat-stored Δ9-tetrahydrocannabinol (THC) into blood is enhanced by food deprivation or ACTH exposure. Br J Pharmacol 158: 1330–1337.
Hindocha C, Freeman TP, Schafer G, Gardener C, Das RK, Morgan CJ et al (2015). Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. Eur Neuropsychopharmacol. 25: 325–334.
Holland ML, Panetta JA, Hoskins JM, Bebawy M, Roufogalis BD, Allen JD et al (2006). The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistantcells. Biochem Pharmacol 71: 1146–1154.
Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D (2012). Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry 201: 481–485.
Inoue T, Katsumata T, Yabuki M, Yamaguchi N, Osada K, Tagawa M et al (2012). Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein. Prog Neuropsychopharmacol Biol Psychiatry 39: 156–162.
Joober R, Boksa P (2010). Clozapine: a distinct, poorly understood and under-used molecule. J Psychiatry Neurosci 35: 147–159.
Juknat A, Pietr M, Kozela E, Rimmerman N, Levy R, Coppola G et al (2012). Differential transcriptional profiles mediated by exposure to the cannabinoids cannabidiol and Delta(9)-tetrahydrocannabinol in BV-2 microglial cells. Br J Pharmacol 165: 2512–2528.
Kapur S, Remington G (2001). Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 50: 873–883.
Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000). Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157: 514–520.
Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W et al (2010). Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 35: 581–590.
Kishi T, Matsuda Y, Nakamura H, Iwata N (2013). Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials. J Psychiatr Res 47: 149–154.
Koskinen J, Löhönen J, Koponen H, Isohanni M, Miettunen J (2010). Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull 36: 1115–1130.
Kreuz DS, Axelrod J (1973). Delta-9-tetrahydrocannabinol: localization in body fat. Science 179: 391–393.
Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB (2010). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull 36: 94–103.
Li L, Du Y, Li N, Wu X, Wu Y (2009). Top-down modulation of prepulse inhibition of the startle reflex in humans and rats. Neurosci Biobehav Rev 33: 1157–1167.
Linnet K, Ejsing TB (2008). A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. Eur Neuropsychopharmacol 18: 157–169.
Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Andreasson S, Allebeck P (2014). Prognosis of schizophrenia in persons with and without a history of cannabis use. Psychol Med 44: 2513–2521.
McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA et al (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163: 600–610.
Meltzer HY, Matsubara S, Lee J (1989). Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251: 238–246.
Mestre L, Correa F, Docagne F, Clemente D, Guaza C (2006). The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE(2) release in murine brain-derived endothelial cells following Theiler's virus infection. Biochem Pharmacol 72: 869–880.
Miksys SL, Cheung C, Gonzalez FJ, Tyndale RF (2005). Human CYP2D6 and mouse CYP2Ds: organ distribution in a humanized mouse model. Drug Metab Dispos 33: 1495–1502.
Montanari F, Ecker GF (2015). Prediction of drug-ABC-transporter interaction—recent advances and future challenges. Adv Drug Deliv Rev 86: 17–26.
Moons T, de Roo M, Claes S, Dom G (2011). Relationship between P-glycoprotein and second-generation antipsychotics. Pharmacogenomics 12: 1193–1211.
Moore TA, Covell NH, Essock SM, Miller AL (2007). Real-world antipsychotic treatment practices. Psychiatr Clin North Am 30: 401–416.
Murray M (2006). Role of CYP pharmacogenetics and drug‐drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J Pharm Pharmacol 58: 871–885.
Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW (2004). Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14: 1–18.
Nichols DE (2004). Hallucinogens. Pharmacol Ther 101: 131–181.
Ouagazzal AM, Jenck F, Moreau JL (2001). Drug-induced potentiation of prepulse inhibition of acoustic startle reflex in mice: a model for detecting antipsychotic activity? Psychopharmacology 156: 273–283.
Patel R, Wilson R, Jackson R, Ball M, Shetty H, Broadbent M et al (2016). Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study. BMJ Open 6: e009888.
Quednow BB, Wagner M, Westheide J, Beckmann K, Bliesener N, Maier W et al (2006). Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine. Biol Psychiatry 59: 536–545.
Reagan-Shaw S, Nihal M, Ahmad N (2008). Dose translation from animal to human studies revisited. FASEB J 22: 659–661.
Remington G, Lee J, Agid O, Takeuchi H, Foussias G, Hahn M et al (2016). Clozapine's critical role in treatment resistant schizophrenia: ensuring both safety and use. Expert Opin Drug Saf 15: 1193–1203.
Schotte A, Janssen P, Gommeren W, Luyten W, Van Gompel P, Lesage A et al (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124: 57–73.
Sheehan J, Sliwa J, Amatniek J, Grinspan A, Canuso C (2010). Atypical antipsychotic metabolism and excretion. Curr Drug Metab 11: 516–525.
Spiro AS, Wong A, Boucher AA, Arnold JC (2012). Enhanced brain disposition and effects of Delta9-tetrahydrocannabinol in P-glycoprotein and breast cancer resistance protein knockout mice. PLoS ONE 7: e35937.
Stauffer VL, Case M, Kinon BJ, Conley R, Ascher-Svanum H, Kollack-Walker S et al (2011). Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Res 187: 42–48.
Sumner BE, Cruise LA, Slattery DA, Hill DR, Shahid M, Henry B (2004). Testing the validity of c-fos expression profiling to aid the therapeutic classification of psychoactive drugs. Psychopharmacology (Berl) 171: 306–321.
Swift W, Wong A, Li KM, Arnold JC, McGregor IS (2013). Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PLoS ONE 8: e70052.
Todd SM, Arnold JC (2016). Neural correlates of cannabidiol and Delta9-tetrahydrocannabinol interactions in mice: implications for medical cannabis. Br J Pharmacol 173: 53–65.
Urichuk L, Prior TI, Dursun S, Baker G (2008). Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab 9: 410–418.
Vann RE, Gamage TF, Warner JA, Marshall EM, Taylor NL, Martin BR et al (2008). Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol. Drug Alcohol Depend 94: 191–198.
Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL (2004). The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmacol 7: 415–419.
Yang J, Kim Y-H, Kwon J-S, Lee S-Y, Lee S-H, Yi J-S et al (2010). Efficacy and tolerability of blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial. Clin Neuropharmacol 33: 169–175.